TY - JOUR

T1 - Ciprofloxacin exposure and adverse pregnancy outcomes

T2 - A Danish nationwide cohort study

AU - Noergaard, Mia

AU - Gotfredsen, Ditte Resendal

AU - Sørensen, Anne Mette Skov

AU - Andersen, Jon Trærup

N1 - Funding Information: MN was supported by a grant from P. Carl Petersens Fond, reference number: 19133. Publisher Copyright: © 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.

PY - 2022

Y1 - 2022

N2 - Objective: To examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations. Design: A nationwide register-based cohort study. Setting: Data were obtained from the Medical Birth Registry, the National Hospital Registry, the Danish National Prescription Registry and Statistics Denmark. Population: Data were collected in the period between 1997 and 2016 and included all registered pregnancies that ended in an elective termination, miscarriage, stillbirth or a live birth. Exposure was defined as redeeming one or more prescriptions of ciprofloxacin. Methods: Miscarriage was defined as a diagnosis given before 22 weeks without any medical intervention. Major malformations were classified according to EUROCAT 1.4. We matched ciprofloxacin-exposed pregnancies to unexposed pregnancies on the propensity score in a ratio 1:4. To estimate the hazard ratio (HR) of miscarriage a Cox proportional hazard regression model was used. A log binomial model was used to estimate the relative risk ratio (RR) of major malformations. Main outcome measures: HR of miscarriage and the RR of major malformations. Results: A total of 1 650 649 pregnancies were identified. Of these, 10 250 (2050 ciprofloxacin-exposed) and 6100 (1220 ciprofloxacin-exposed) were included in the miscarriage and major malformation analysis, respectively. The HR of miscarriage was 0.99 (95% confidence interval [CI] 0.84–1.17). For major malformation, the RR was 1.01 (95% CI 0.72–1.40). For the organ-specific major malformations and the sensitivity analyses, no significant increased risks were identified. Conclusion: We demonstrated no association between miscarriage and maternal ciprofloxacin exposure within the first 22 weeks of pregnancy, or between major malformations and maternal exposure during the first trimester. Tweetable abstract: No association between maternal ciprofloxacin exposure and adverse pregnancy outcomes.

AB - Objective: To examine the association between maternal exposure to ciprofloxacin and the risk of miscarriage and major malformations. Design: A nationwide register-based cohort study. Setting: Data were obtained from the Medical Birth Registry, the National Hospital Registry, the Danish National Prescription Registry and Statistics Denmark. Population: Data were collected in the period between 1997 and 2016 and included all registered pregnancies that ended in an elective termination, miscarriage, stillbirth or a live birth. Exposure was defined as redeeming one or more prescriptions of ciprofloxacin. Methods: Miscarriage was defined as a diagnosis given before 22 weeks without any medical intervention. Major malformations were classified according to EUROCAT 1.4. We matched ciprofloxacin-exposed pregnancies to unexposed pregnancies on the propensity score in a ratio 1:4. To estimate the hazard ratio (HR) of miscarriage a Cox proportional hazard regression model was used. A log binomial model was used to estimate the relative risk ratio (RR) of major malformations. Main outcome measures: HR of miscarriage and the RR of major malformations. Results: A total of 1 650 649 pregnancies were identified. Of these, 10 250 (2050 ciprofloxacin-exposed) and 6100 (1220 ciprofloxacin-exposed) were included in the miscarriage and major malformation analysis, respectively. The HR of miscarriage was 0.99 (95% confidence interval [CI] 0.84–1.17). For major malformation, the RR was 1.01 (95% CI 0.72–1.40). For the organ-specific major malformations and the sensitivity analyses, no significant increased risks were identified. Conclusion: We demonstrated no association between miscarriage and maternal ciprofloxacin exposure within the first 22 weeks of pregnancy, or between major malformations and maternal exposure during the first trimester. Tweetable abstract: No association between maternal ciprofloxacin exposure and adverse pregnancy outcomes.

U2 - 10.1111/1471-0528.17083

DO - 10.1111/1471-0528.17083

M3 - Journal article

C2 - 34954900

AN - SCOPUS:85122760461

VL - 129

SP - 1503

EP - 1511

JO - British Journal of Obstetrics and Gynaecology, Supplement

JF - British Journal of Obstetrics and Gynaecology, Supplement

SN - 0140-7686

IS - 9

ER -